Clinical Cancer Research, Vol 3, Issue 2 273-279, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells

M Drees, WA Dengler, T Roth, H Labonte, J Mayo, L Malspeis, M Grever, EA Sausville and HH Fiebig
Department of Internal Medicine, University of Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany.

We have selected a panel of human tumor xenografts for in vitro and in vivo studies that allows an indication of selectivity of action of novel chemotherapeutic agents. We report here the antitumor activity of the flavone flavopiridol (previously designated L86-8275), which has been selected for further studies based in part on its behavior in the anticancer drug screening system of the United States National Cancer Institute. Eighteen human tumor and five cell line-derived xenografts established by serial passage in nude mice in our laboratory were used as tumor models for in vitro investigations using a modified double-layer soft agar assay. In vivo investigations were completed in nude mice bearing advanced-stage s.c. growing prostate cancer xenografts. Antitumor activity in vitro (test/control </= 30%) of flavopiridol was observed at the very low concentration of 0.1 ng/ml in three of four prostatic xenografts and in one melanoma xenograft. Overall, in 14 of 23 (61%) tumor xenografts, drug treatment resulted in a IC70 of <10 ng/ml, demonstrating the high antiproliferative potential of flavopiridol. Toxicity to in vitro bone marrow cultures was evident only at 100 ng/ml, indicating potential high selectivity for susceptible tumor cells. Comparison of tumor cells with bone marrow samples tested showed clear prostate carcinoma and moderate melanoma selectivity. In vivo studies of flavopiridol confirmed antitumor activity in both prostate cancer xenografts investigated. At the maximal tolerated dose of 10 mg/kg/day administered p.o. on days 1-4 and 7-11, flavopiridol effected tumor regression in PRXF1337 and tumor stasis lasting for 4 weeks in PRXF1369. We conclude that flavopiridol shows strong prostate-and moderate melanoma-specific antitumor activity in vitro. The prostate antitumor activity is also reflected by the two in vivo models studied. Initial clinical efforts with flavopiridol might consider early evaluation in patients with prostate carcinoma.

This article has been cited by other articles:

				Y. K. Lee, C. R. Isham, S. H. Kaufman, and K. C. Bible Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy Mol. Cancer Ther., January 1, 2006; 5(1): 138 - 148. [Abstract] [Full Text] [PDF]

				K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid, M. M. Ames, C. R. Isham, J. Piens, S. L. Rubin, J. Rubin, et al. Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points Clin. Cancer Res., August 15, 2005; 11(16): 5935 - 5941. [Abstract] [Full Text] [PDF]

				M. Puppo, S. Pastorino, G. Melillo, A. Pezzolo, L. Varesio, and M. C. Bosco Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation Clin. Cancer Res., December 15, 2004; 10(24): 8704 - 8719. [Abstract] [Full Text] [PDF]

				G. Liu, D. R. Gandara, P. N. Lara Jr., D. Raghavan, J. H. Doroshow, P. Twardowski, P. Kantoff, W. Oh, K. Kim, and G. Wilding A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer Clin. Cancer Res., February 1, 2004; 10(3): 924 - 928. [Abstract] [Full Text] [PDF]

				L. M. Schang Cyclin-dependent kinases as cellular targets for antiviral drugs J. Antimicrob. Chemother., December 1, 2002; 50(6): 779 - 792. [Abstract] [Full Text] [PDF]

				L. M. Schang, A. Bantly, M. Knockaert, F. Shaheen, L. Meijer, M. H. Malim, N. S. Gray, and P. A. Schaffer Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins J. Virol., June 27, 2002; 76(15): 7874 - 7882. [Abstract] [Full Text] [PDF]

				B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger, P. Klingler, A. M. Senderowicz, E. A. Sausville, and W. Jäger In Vitro Glucuronidation of the Cyclin-Dependent Kinase Inhibitor Flavopiridol by Rat and Human Liver Microsomes: Involvement of UDP-Glucuronosyltransferases 1A1 and 1A9 Drug Metab. Dispos., April 1, 2001; 29(4): 407 - 414. [Abstract] [Full Text]

				F. Innocenti, W. M. Stadler, L. Iyer, J. Ramírez, E. E. Vokes, and M. J. Ratain Flavopiridol Metabolism in Cancer Patients Is Associated with the Occurrence of Diarrhea Clin. Cancer Res., September 1, 2000; 6(9): 3400 - 3405. [Abstract] [Full Text]

				K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann Flavopiridol Binds to Duplex DNA Cancer Res., May 1, 2000; 60(9): 2419 - 2428. [Abstract] [Full Text]

				K. C. Bible, S. A. Boerner, K. Kirkland, K. L. Anderl, D. Bartelt Jr., P. A. Svingen, T. J. Kottke, Y. K. Lee, S. Eckdahl, P. G. Stalboerger, et al. Characterization of an Ovarian Carcinoma Cell Line Resistant to Cisplatin and Flavopiridol Clin. Cancer Res., February 1, 2000; 6(2): 661 - 670. [Abstract] [Full Text]

				G. Melillo, E. A. Sausville, K. Cloud, T. Lahusen, L. Varesio, and A. M. Senderowicz Flavopiridol, a Protein Kinase Inhibitor, Down-Regulates Hypoxic Induction of Vascular Endothelial Growth Factor Expression in Human Monocytes Cancer Res., November 1, 1999; 59(21): 5433 - 5437. [Abstract] [Full Text] [PDF]

				G. I. Shapiro, D. A. Koestner, C. B. Matranga, and B. J. Rollins Flavopiridol Induces Cell Cycle Arrest and p53-independent Apoptosis in Non-Small Cell Lung Cancer Cell Lines Clin. Cancer Res., October 1, 1999; 5(10): 2925 - 2938. [Abstract] [Full Text] [PDF]

				J. Ruef, A. S. Meshel, Z. Hu, C. Horaist, C. A. Ballinger, L. J. Thompson, V. D. Subbarao, J. A. Dumont, and C. Patterson Flavopiridol Inhibits Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat Circulation, August 10, 1999; 100(6): 659 - 665. [Abstract] [Full Text] [PDF]

				F. Arguello, M. Alexander, J. A. Sterry, G. Tudor, E. M. Smith, N. T. Kalavar, J. F. Greene Jr, W. Koss, C. D. Morgan, S. F. Stinson, et al. Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts Blood, April 1, 1998; 91(7): 2482 - 2490. [Abstract] [Full Text] [PDF]

				N. G. Oikonomakos, J. B. Schnier, S. E. Zographos, V. T. Skamnaki, K. E. Tsitsanou, and L. N. Johnson Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site J. Biol. Chem., October 27, 2000; 275(44): 34566 - 34573. [Abstract] [Full Text] [PDF]